Q-omics provides the consensus-scored KLHL36 profile across patient tissues and cancer cell-line models. KLHL36 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KLHL36 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, KLHL36 RNA expression shows 20,304 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where KLHL36 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL36 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL36 survival associations across molecular data types. KLHL36 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL36 RNA expression–survival associations across cancer types. High KLHL36 expression shows unfavorable associations in CESC and ACC, but favorable associations in KIRP, KIRC, SCLC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for KLHL36 RNA expression.
This table summarizes KLHL36 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL36. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL36 shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRP, LIHC, KIRC and CHOL. The HNSC box plot shows higher KLHL36 RNA expression in tumor versus normal tissue (log2 FC = +0.633, t-test p < 0.001).
This table shows molecular features associated with KLHL36 in patient tissues and cancer cell lines. In patient samples, KLHL36 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL36 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
